, Volume 123, Issue 5, pp 751-752
Date: 11 Mar 2012

Natalizumab-associated complication? First case of peripheral T cell lymphoma

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Natalizumab (TYSABRI, Biogen Idec) is a therapeutic monoclonal antibody approved in 2004 for treatment of patients with the relapsing form of multiple sclerosis (MS). The drug reduces MS relapses, as well as new inflammatory lesions on MRI, and is highly clinically effective. Unfortunately, soon after approval, occurrence of progressive multifocal leukoencephalopathy (PML), due to reactivation of JC virus was reported with use of drug in two MS patients [6, 8] and one with inflammatory bowel disease [15]. Natalizumab was temporarily removed from the market. Availability resumed in 2006 with monitoring programs in place, including serological testing for JC virus exposure [3, 4]. As of 31 December 2011, over 95,300 patients have used natalizumab worldwide and, despite cautious use, 207 PML cases have occurred (https://medinfo.biogenidec.com). Other rare neoplastic [13] and infectious [2] complications seen in immunosuppressed patients are also starting to be reported.

A 39-year-old woman ...

Accepted for abstract presentation at the 101st annual United States and Canadian Pathology meeting, Vancouver, B.C., March 2012.